PLAU and cancer: Another small molecule inhibitor, WX-UK1, which is a metabolite of Mesupron, has also demonstrated notable efficacy in preclinical models by reducing the invasiveness of various cancer cell types and inhibiting tumor growth through the blockade of uPA’s enzymatic activity [6].